Critical Reviews in Oncology / Hematology
Volume 74, Issue 3 , Pages 163-174 , June 2010

Review role of topotecan in gynaecological cancers: Current indications and perspectives

  • Domenica Lorusso

      Affiliations

    • Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, IT-00168 Rome, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 06 3550 8736; fax: +39 06 3550 8736.
    • ,
  • Antonella Pietragalla

      Affiliations

    • Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, IT-00168 Rome, Italy
    • ,
  • Sara Mainenti

      Affiliations

    • Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, IT-00168 Rome, Italy
    • ,
  • Valeria Masciullo

      Affiliations

    • Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, IT-00168 Rome, Italy
    • ,
  • Giovanni Di Vagno

      Affiliations

    • Casa Sollievo della Sofferenza, S. Giovanni Rotondo (Foggia), Italy
    • ,
  • Giovanni Scambia

      Affiliations

    • Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, IT-00168 Rome, Italy

,Accepted 11 August 2009.

References 

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481–488
  3. Vasey PA, Herrstedt J, Jelic S. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma. Ann Oncol. 2005;16(Suppl. 1):i13–i15
  4. Herzog TJ, Holloway RW, Stuart GC. Workshop: options for therapy in ovarian cancer. Gynecol Oncol. 2003;90:S45–50
  5. Lhomme C, Morice P, Planchamp F, et al. Clinical practice guidelines 2008 for the surgical treatment, medical first-line and consolidation treatments of patients with epithelial ovarian cancer—update. According to the methodology of Standards, Options: Recommendations (SOR). Bull Cancer. 2008;95:881–886
  6. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16:3345–3352
  7. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol. 1996;14:3056–3061
  8. Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol. 2009;36:112–125
  9. O’Byrne KJ, Bliss P, Graham JD, et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. Proc Am Soc Clin Oncol. 2002;21:[abstr 808]
  10. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8
  11. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–2106
  12. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–4707
  13. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBO-CAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base 2004; 5 version. Lyon: IARC Press; 2004;
  14. Green JA, De Barros Lopes A. Optimizing treatment for cervical cancer: the value of chemoradiation. Am J Cancer. 2004;3:215–227(13)
  15. Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervix cancer: a systematic review and meta-analysis of individual patient data from 21 randomized controlled trials. Eur J Cancer. 2003;39:2470–2486
  16. Distefano M, Ferrandina G, Smaniotto D, et al. Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility. Oncology. 2004;67:103–111
  17. Brader KR, Morris M, Levenback C, Levy L, Lucas KR, Gershenson DM. Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol. 1998;16:1879–1884
  18. Burris HA, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst. 1992;84:1816–1820
  19. Burris HA, Fields SM. Topoisomerase I inhibitors. An overview of the camptothecin analogs. Hematol Oncol Clin North Am. 1994;8:333–355
  20. Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995;36:393–403
  21. Pappo AS, Lyden E, Breneman J, et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. J Clin Oncol. 2001;19:213–219
  22. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993;85:271–291
  23. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep. 1972;56:515–521
  24. Slichenmyer WJ, Rowinsky EK, Grochow LB, Kaufmann SH, Donehower RC. Camptothecin analogues: studies from the Johns Hopkins Oncology Center. Cancer Chemother Pharmacol. 1994;34(Suppl.):S53–S57
  25. Wall ME, Wani MC, Cook CE, et al. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 1966;88:3888–3890
  26. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep. 1970;54:461–470
  27. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep. 1972;56:95–101
  28. Potmesil M, Hsiang YH, Liu LF, et al. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res. 1988;48:3537–3543
  29. Lorusso D, Mainenti S, Scambia G. Ruolo di topotecan in Ginecologia Oncologica. Pacini Editore; 2008.
  30. Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol. 1988;34:755–760
  31. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;260:14873–14878
  32. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989;49:5077–5082
  33. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988;48:1722–1726
  34. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure–activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 1989;49:1465–1469
  35. O’Connor PM, Nieves-Neira W, Kerrigan D, et al. Aphidicolin protects non S-phase human colon carcinoma HT-29 cells against killing by camptothecin. Proc AACR. 1991;32:336
  36. Takimoto CH, Arbuck SG. Clinical status and optimal use of topotecan. Oncology (Williston Park). 1997;11:1635–1646[discussion 49–51, 55–57]
  37. Wang JC, Liu LF. DNA topoisomerases. Enzymes that catalyze the concerted breaking and rejoining of DNA bonds. In:  Tayler JH editors. Molecular genetics, Part III. Academic Press; 1979;p. 65–88
  38. Wang JC. Interaction between DNA and an Escherichia coli protein omega. J Mol Biol. 1971;55:523–533
  39. Wang JC. Recent studies of DNA topoisomerases. Biochim Biophys Acta. 1987;909:1–9
  40. Wani MC, Nicholas AW, Manikumar G, Wall ME. Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure–activity correlations. J Med Chem. 1987;30:1774–1779
  41. Wani MC, Nicholas AW, Wall ME. Plant antitumor agents. 28. Resolution of a key tricyclic synthon, 5′(RS)-1,5-dioxo-5′-ethyl-5′-hydroxy-2′H,5′H,6′H-6′-oxopyrano[3′,4′- f]delta 6,8-tetrahydro-indolizine: total synthesis and antitumor activity of 20(S)- and 20(R)-camptothecin. J Med Chem. 1987;30:2317–2319
  42. Zhang H, D’Arpa P, Liu LF. A model for tumor cell killing by topoisomerase poisons. Cancer Cells. 1990;2:23–27
  43. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351–375
  44. Mattern MR, Zwelling LA, Kerrigan D, Kohn KW. The reconstitution of higher-order DNA structure after X-irradiation of mammalian cells. Biochem Biophys Res Commun. 1983;112:1077–1084
  45. Tan KB, Mattern MR, Boyce RA, Hertzberg RP, Schein PS. Elevated topoisomerase II activity and altered chromatin in nitrogen mustard-resistant human cells. NCI Monogr. 1987;95–98
  46. Capranico G, Zunino F. DNA topoisomerase-trapping antitumour drugs. Eur J Cancer. 1992;28A:2055–2060
  47. Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 1973;33:2834–2836
  48. Kingsbury WD, Boehm JC, Jakas DR, et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem. 1991;34:98–107
  49. Sanghavi SN, Needle MN, Krailo MD, Geyer JR, Ater J, Mehta MP. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952. Neuro Oncol. 2003;5:8–13
  50. Del Bino G, Lassota P, Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res. 1991;193:27–35
  51. Davies BE, Minthorn EA, Dennis MJ, Rosing H, Beijnen JH. The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog. Pharm Res. 1997;14:1461–1465
  52. Herben VM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet. 1996;31:85–102
  53. Korfel A, Oehm C, von Pawel J, et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study. Eur J Cancer. 2002;38:1724–1729
  54. Wall JG, Burris HA, Von Hoff DD, et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs. 1992;3:337–345
  55. von Pawel J. The role of topotecan in treating small cell lung cancer: second-line treatment. Lung Cancer. 2003;41(Suppl. 4):S3–8
  56. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer. 2002;38:57–63
  57. Data on file. SmithKline Beecham Pharmaceuticals; 1999.
  58. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res. 1993;53:725–727
  59. Schutte W, Manegold C, von Pawel JV, et al. Topotecan—a new treatment option in the therapy of brain metastases of lung cancer. Front Radiat Ther Oncol. 1999;33:354–363
  60. van Warmerdam LJ, Creemers GJ, Rodenhuis S, et al. Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer Chemother Pharmacol. 1996;38:254–260
  61. Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol. 2001;83:257–262
  62. Huber RM, Reck M, Gosse H, et al. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur Respir J. 2006;27(6):1183–1189
  63. Armstrong DK. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist. 2004;9:33–42
  64. Huber RM, Gatzemeier U, Gosse H, et al. Topotecan in second-line therapy of SCLC: impact on survival?. Onkologie. 2000;23(Suppl. 3):9–12
  65. Mould DR, Holford NH, Schellens JH, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther. 2002;71:334–348
  66. Mobus V, Pfaff PN, Kreienberg R. Topotecan (Hycamtin) in the therapy of recurrent ovarian carcinoma. Onkologie. 1998;21(Suppl. 4):2–5
  67. Mobus V, Lane S, Fields SZ, et al. Topotecan: tolerability, response rate and survival associated with extended therapy in relapsed ovarian cancer—results of a pooled analysis of 523 patients. Eur J Oncol. 1999;35(Suppl. 4):
  68. Gemmern vR. Gewebetoxizitat und Paravasatbehandlung neuer Zytostatika (Soft tissue toxicity and treatment of extravasation of new cytostatics). Krankenhauspharmazie. 1996;17:471–473
  69. Oostweegel LMM, Varmerdam JC, Schot M, et al. Extravasation of topotecan: a report of two cases. J Oncol Pharmacy Pract. 1997;3:115–116
  70. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:405–410
  71. Bajetta E, Di Leo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1996;14:2546–2551
  72. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183–2193
  73. De Placido S, Scambia G, Di Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol. 2004;22:2635–2642
  74. Herzog TJ. Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist. 2002;7(Suppl. 5):3–10
  75. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312–3322
  76. Vecchione F, Fruscio R, Dell’Anna T, et al. A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:367–372
  77. Hochster HS, Plimack ER, Mandeli J, et al. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study. Gynecol Oncol. 2006;100:324–329
  78. Guppy AE, Nelstrop AE, Foster T, Agarwal R, Seckl MJ, Rustin GJ. A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. Br J Cancer. 2004;90:810–814
  79. Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006;98:1036–1045
  80. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419–1425
  81. Armstrong D, O’Reilly S. Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist. 1998;3:4–10
  82. Cass I, Kuo DY, Fields AL, Runowicz CD, Goldberg GL. Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan. Gynecol Oncol. 1998;69:175–178
  83. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol. 2000;79:116–119
  84. Safra T, Menczer J, Bernstein R, et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol. 2007;105:205–210
  85. Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2008;108:53–57
  86. Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14:1552–1557
  87. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6
  88. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 1997;66:480–486
  89. Sehouli J, Oskay-Ozcelik G. Current role and future aspects of topotecan in relapsed ovarian cancer. Curr Med Res Opin. 2009;25:639–651
  90. Clarke-Pearson DL, Van Le L, Iveson T, et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol. 2001;19:3967–3975
  91. Rose PG, Smrekar M, Haba P, Visser C, Beeler JF. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecol Oncol. 2005;99:714–719
  92. Koensgen D, Stengel D, Belau A, et al. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study. Cancer Chemother Pharmacol. 2008;62:393–400
  93. Bolis G, Scarfone G, Sciatta C, et al. A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol. 2001;83:477–480
  94. Thigpen T, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol. 1995;22:67–75
  95. Randall-Whitis LM, Monk BJ. Topotecan in the management of cervical cancer. Expert Opin Pharmacother. 2007;8:227–236
  96. Ling YH, Donato NJ, Perez-Soler R. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. Cancer Chemother Pharmacol. 2001;47:473–480
  97. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 1994;86:1517–1524
  98. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol. 1998;41:385–390
  99. Long HJ, Bundy BN, Grendys EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626–4633
  100. Buda A, Fossati R, Colombo N, et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol. 2005;23:4137–4145
  101. Zanaboni FGB, Kusamura S, Ditto A, et al. Weekly topotecan and cisplatin (TOPOCIS) as neoajuvant chemotherapy for locally-advanced squamous cervical carcinoma: results of a phase II study. Proc Am Soc Clin Oncol:. 2008;[abstr 16500]
  102. McGuire WP, Blessing JA, Bookman MA, et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2000;18:1062–1067

PII: S1040-8428(09)00158-9

doi: 10.1016/j.critrevonc.2009.08.001

Critical Reviews in Oncology / Hematology
Volume 74, Issue 3 , Pages 163-174 , June 2010

Article Tools

* Image Usage & Resolution